---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-22-009118"
form_type: "8-K"
ticker: "RCKT"
cik: "0001281895"
company_name: "ROCKET PHARMACEUTICALS, INC."
filed_at: "2022-03-11T23:59:59+00:00"
generated_at: "2026-06-26T23:31:01.717589+00:00"
event_type: "leadership"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Rocket Pharmaceuticals CFO resigns; appoints interim CFO and new director

## Summary
- Fady Malik appointed to Board effective Mar 10; granted options for 33,199 shares (3-yr vest) and 8,641 shares (1-yr vest).
- CFO Carlos Garcia-Parada resigns effective Mar 16 due to personal reasons; will advise through Mar 31.
- John Militello, VP Finance and Controller, appointed interim Principal Financial Officer as of Mar 16.
- Dr. Malik is EVP R&D at Cytokinetics, cardiologist, clinical professor at UCSF.

## SEC filing metadata
- accession: 0001140361-22-009118
- form_type: 8-K
- ticker: RCKT
- cik: 0001281895
- company_name: ROCKET PHARMACEUTICALS, INC.
- filed_at: 2022-03-11T23:59:59+00:00
- event_type: leadership
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1281895/000114036122009118/0001140361-22-009118-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1281895/000114036122009118/brhc10035116_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-22-009118
- JSON: https://secwatch.observer/filing/0001140361-22-009118.json
- Plain text: https://secwatch.observer/filing/0001140361-22-009118.txt

## Key facts
- Executive change
  Fady Malik was appointed as Director at ROCKET PHARMACEUTICALS, INC..
  - Action: appointed
  - Role: Director
  source text: appointed Fady Malik, M.D., Ph.D., to the Board, effective March 10, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1281895/000114036122009118/0001140361-22-009118-index.htm
- Executive change
  Carlos Garcia-Parada resigned as Chief Financial Officer and Principal Financial Officer at ROCKET PHARMACEUTICALS, INC..
  - Action: resigned
  - Role: Chief Financial Officer and Principal Financial Officer
  source text: Carlos Garcia-Parada tendered his resignation as Chief Financial Officer and Principal Financial Officer of the Company, effective March 16, 2022, due to personal reasons.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1281895/000114036122009118/0001140361-22-009118-index.htm
- Executive change
  John Militello was appointed as Interim Principal Financial Officer at ROCKET PHARMACEUTICALS, INC..
  - Action: appointed
  - Role: Interim Principal Financial Officer
  source text: John Militello, the Company’s Vice President – Finance, Senior Controller, Treasurer and Principal Accounting Officer, was appointed as the interim Principal Financial Officer of the Company, as of the effective date of Mr. Garcia-Parada’s resignation.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1281895/000114036122009118/0001140361-22-009118-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.